Atara amends Pierre Fabre deal: cuts regulatory milestones by $9M, adds $15M commercial milestone

Atara Biotherapeutics, Inc.

Regulatory milestone payments from Pierre Fabre reduced from $40M to $31M (decrease of $9M).
New $15M commercial milestone payable upon Product Net Sales exceeding a confidential threshold.
Amendment also modifies other payment sections (redacted) in the commercialization agreement.
Atara submitted BLA for tab-cel (EBV+ PTLD) to FDA in May 2024; Pierre Fabre has exclusive U.S. commercialization rights.
Agreement originally dated October 2023; fourth amendment effective December 30, 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Atara Biotherapeutics, Inc. amended Fourth Amendment with Pierre Fabre Medicament valued at from $40.0 million to $31.0 million (effective 2025-12-30).

Action: amendment
Agreement: collaboration
Counterparty: Pierre Fabre Medicament
Value: from $40.0 million to $31.0 million
Effective: 2025-12-30

Exact text from the filing

Under the terms of the Amendment, the Company has agreed to reduce the aggregate amount of potential milestone payments payable by Pierre Fabre to the Company upon achieving certain regulatory milestones relating to the approval by the FDA of a BLA for tab-cel from $40.0 million to $31.0 million for the right to receive an additional $15.0 million potential milestone payment from Pierre Fabre to the Company upon achieving a certain commercial milestone.

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-000907

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.